Spermicide used alone for contraception

David A Grimes; Laureen M Lopez; Elizabeth G. Raymond; Vera Halpern; Kavita Nanda; Kenneth F Schulz

doi:10.1002/14651858.CD005218.pub4

Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados
Guías
Temas

Revisiones y protocolos relacionados

Topics

Temas


Study	Site	Nonoxynol‐9 sponge	Menfegol tablet
Chi 1987	Belgrade	3.8	6.2
Chi 1987	Maribor	11.7	12.7
Chi 1987	Taiwan	18.2	29.9

Analysis 1.1

Comparison 1 Collatex vaginal sponge (nonoxynol‐9 1.15 g) versus Neo Sampoon tablet (menfegol 60 mg), Outcome 1 Life‐table rates per 100 women for pregnancy (12‐month).

Ir a la figura de la revisión


Study	Site	Nonoxynol‐9 sponge	Menfegol tablet
Chi 1987	Begrade	5.3	4.3
Chi 1987	Maribor	9.1	7.7
Chi 1987	Taiwan	44.9	32.6
Chi 1987	Bangladesh	88.5	20.2

Analysis 1.2

Comparison 1 Collatex vaginal sponge (nonoxynol‐9 1.15 g) versus Neo Sampoon tablet (menfegol 60 mg), Outcome 2 Life‐table rates per 100 women for discontinuation due to personal reasons (6‐month).

Ir a la figura de la revisión


Study	Site	Nonoxynol‐9 sponge	Menfegol tablet
Chi 1987	Belgrade	13.0	9.5
Chi 1987	Maribor	14.8	15.6
Chi 1987	Taiwan	48.9	49.5
Chi 1987	Bangladesh	97.7	22.3

Analysis 1.3

Comparison 1 Collatex vaginal sponge (nonoxynol‐9 1.15 g) versus Neo Sampoon tablet (menfegol 60 mg), Outcome 3 Life‐table rates per 100 women for discontinuation due to personal reasons (12‐month).

Ir a la figura de la revisión


Study	Nonoxynol‐9 tablet	Menfegol tablet
Chompootaweep 1990	15.2	13.3
Ghunney 1987	11.8	0
Klufio 1988	2.9	3.1
Ruoff 1988	10.3	14.7

Analysis 2.1

Comparison 2 Ortho vaginal tablets: nonoxynol‐9 100 mg versus menfegol 60 mg, Outcome 1 Life‐table rates per 100 women for pregnancy (6‐month).

Ir a la figura de la revisión


Study	Nonoxynol‐9 tablet	Menfegol tablet
Chompootaweep 1990	31.7	25.3
Klufio 1988	14.0	15.8

Analysis 2.2

Comparison 2 Ortho vaginal tablets: nonoxynol‐9 100 mg versus menfegol 60 mg, Outcome 2 Life‐table rates per 100 women for pregnancy (12‐month).

Ir a la figura de la revisión


Study	Time frame	Nonoxynol‐9 tablet	Menfegol tablet
Chompootaweep 1990	12 months	37.7	30.0
Ghunney 1987	6 months	13.4	0
Klufio 1988	6 months	16.2	15.9
Ruoff 1988	12 months	36.9	45.1

Analysis 2.3

Comparison 2 Ortho vaginal tablets: nonoxynol‐9 100 mg versus menfegol 60 mg, Outcome 3 Pearl index per 100 woman‐years.

Ir a la figura de la revisión


Study	Time frame	Nonoxynol‐9 tablet	Menfegol tablet
Chompootaweep 1990	6‐month	10.1	13.4
Chompootaweep 1990	12‐month	13.5	16.2
Klufio 1988	6‐month	5.8	1.5
Klufio 1988	12‐month	5.8	1.5

Analysis 2.4

Comparison 2 Ortho vaginal tablets: nonoxynol‐9 100 mg versus menfegol 60 mg, Outcome 4 Life‐table rates per 100 women for discontinuation due to discomfort.

Ir a la figura de la revisión


Study	Time frame	Brand of nonoxynol‐9	Nonoxynol‐9 100 mg	Menfegol 60 mg
Abdelsalaam 1984	6‐month	Emko	10.6	6.7
Kazi 1992	12‐month	Ortho	22.5	15.2
Lamptey 1985	12‐month 12‐month	Ortho Emko	11.3 12.5	9.6 9.6

Analysis 3.1

Comparison 3 Ortho or Emko tablet (nonoxynol‐9 100 mg) versus Neo Sampoon tablet (menfegol 60 mg), Outcome 1 Life‐table rates per 100 women for pregnancy.

Ir a la figura de la revisión


Study	Time frame	Nonoxynol‐9 brand	Nonoxynol‐9 100 mg	Menfegol 60 mg	Assessment
Abdelsalaam 1984	6‐month	Emko	2.4	5.8	discomfort
Kazi 1992	12‐month	Ortho Conceptrol	23.9	17.4	medical reasons including discomfort
Lamptey 1985	12‐month	Ortho Vaginal Emko	2.7 12.8	0 0	discomfort

Analysis 3.2

Comparison 3 Ortho or Emko tablet (nonoxynol‐9 100 mg) versus Neo Sampoon tablet (menfegol 60 mg), Outcome 2 Life‐table rates per 100 women for discontinuation due to discomfort and/or medical reasons.

Ir a la figura de la revisión


Study	Time frame	Nonoxynol‐9 Ortho	Nonoxynol‐9 Emko
Lamptey 1985	12‐month	11.3	12.5
Poindexter 1984	6‐month	12.4	13.2
Younis 1985	12‐month	19.0	18.7

Analysis 4.1

Comparison 4 Ortho tablet (nonoxynol‐9 100 mg) versus Emko tablet (nonoxynol‐9 100 mg), Outcome 1 Life‐table rates per 100 women for pregnancy.

Ir a la figura de la revisión


Study	Time frame	Nonoxynol‐9 Ortho	Nonoxynol‐9 Emko
Lamptey 1985	12‐month	2.7	12.8
Poindexter 1984	6‐month	5.9	15.6
Younis 1985	12‐month	11.6	5.8

Analysis 4.2

Comparison 4 Ortho tablet (nonoxynol‐9 100 mg) versus Emko tablet (nonoxynol‐9 100 mg), Outcome 2 Life‐table rates per 100 women for discontinuation due to discomfort.

Ir a la figura de la revisión


Study	Nonoxynol‐9 8% foam	Menfegol tablet
Andolsek 1988	19.3	12.8
Youssef 1987	2.1	2.8

Analysis 5.1

Comparison 5 Emko foam (nonoxynol‐9 8% concentration) versus Neo Sampoon tablet (menfegol 60 mg), Outcome 1 Life‐table rates per 100 women for pregnancy (12‐month).

Ir a la figura de la revisión


Study	Nonoxynol‐9 8% foam	Menfegol tablet
Andolsek 1988	32.1	24.0
Youssef 1987	2.6	2.6

Analysis 5.2

Comparison 5 Emko foam (nonoxynol‐9 8% concentration) versus Neo Sampoon tablet (menfegol 60 mg), Outcome 2 Life‐table rates per 100 women for discontinuation due to discomfort (12‐month).

Ir a la figura de la revisión


Study	Tablet 100 mg	VCF film 72 mg
Raymond 1999	28.0	24.9

Analysis 6.1

Comparison 6 Ortho tablet (nonoxynol‐9 100 mg) versus VCF film (nonoxynol‐9 72 mg), Outcome 1 Probability of pregnancy through six months of typical use.

Ir a la figura de la revisión


Study	Brand name	Dose	Pregnancy probability
Raymond 2004	Advantage S gel	52.5 mg	22.2%
Raymond 2004	Ortho Conceptrol gel	100 mg	15.5%
Raymond 2004	Ortho Conceptrol gel	150 mg	14.0%
Raymond 2004	Ortho Conceptrol film	100 mg	11.9%
Raymond 2004	Encare suppository	100 mg	10.0%

Analysis 7.1

Comparison 7 Nonoxynol‐9 gels (52.5 mg, 100 mg, 150 mg); Nonoxynol‐9 film 100 mg; Nonoxynol‐9 suppository 100 mg, Outcome 1 Probability of pregnancy through six months of typical use.

Ir a la figura de la revisión


Study	Brand name	Dose	Discontinued
Raymond 2004	Advantage S gel	52.5 mg	15%
Raymond 2004	Ortho Conceptrol gel	100 mg	17%
Raymond 2004	Ortho Conceptrol gel	150 mg	18%
Raymond 2004	Ortho Conceptrol film	100 mg	18%
Raymond 2004	Encare suppository	100 mg	17%

Analysis 7.2

Comparison 7 Nonoxynol‐9 gels (52.5 mg, 100 mg, 150 mg); Nonoxynol‐9 film 100 mg; Nonoxynol‐9 suppository 100 mg, Outcome 2 Discontinued method early.

Ir a la figura de la revisión


Study	Brand name	Dose	Liked "very much"
Raymond 2004	Advantage S gel	52.5 mg	46%
Raymond 2004	Ortho Conceptrol gel	100 mg	49%
Raymond 2004	Ortho Conceptrol gel	150 mg	43%
Raymond 2004	Ortho Conceptrol film	100 mg	41%
Raymond 2004	Encare suppository	100 mg	34%

Analysis 7.3

Comparison 7 Nonoxynol‐9 gels (52.5 mg, 100 mg, 150 mg); Nonoxynol‐9 film 100 mg; Nonoxynol‐9 suppository 100 mg, Outcome 3 Liked the method "very much".

Ir a la figura de la revisión

Table 1. Summary of spermicides tested

Brand name	Spermicide and dose	Trial
Neo Sampoon	Menfegol 60 mg	Abdelsalaam 1984
		Andolsek 1988
		Chi 1987
		Kazi 1992
		Lamptey 1985
		Youssef 1987
Ortho menfegol foaming tablet	Menfegol 60 mg	Chompootaweep 1990
		Ghunney 1987
		Klufio 1988
		Ruoff 1988
Collatex sponge	Nonoxynol‐9 1.15 g	Chi 1987
Emko tablet	Nonoxynol‐9 100 mg	Abdelsalaam 1984
		Andolsek 1988
		Lamptey 1985
		Poindexter 1984
		Younis 1985
Emko foam	Nonoxynol‐9 8%	Andolsek 1988
		Youssef 1987
Ortho foaming tablet	Nonoxynol‐9 100 mg	Chompootaweep 1990
		Ghunney 1987
		Klufio 1988
		Ruoff 1988
Ortho tablet	Nonoxynol‐9 100 mg	Kazi 1992
		Lamptey 1985
		Poindexter 1984
		Younis 1985
Ortho tablet	Nonoxynol‐9 100 mg	Raymond 1999
VCF film	Nonoxynol‐9 72 mg	Raymond 1999
Advantage S gel	Nonoxynol‐9 52.5 mg	Raymond 2004
Ortho Conceptrol gel	Nonoxynol‐9 100 mg	Raymond 2004
Ortho Conceptrol gel	Nonoxynol‐9 150 mg	Raymond 2004
Ortho Conceptrol film	Nonoxynol‐9 100 mg	Raymond 2004
Encare suppository	Nonoxynol‐9 100 mg	Raymond 2004

Table 1. Summary of spermicides tested

Ir a la tabla de la revisión

Comparison 1. Collatex vaginal sponge (nonoxynol‐9 1.15 g) versus Neo Sampoon tablet (menfegol 60 mg)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Life‐table rates per 100 women for pregnancy (12‐month) Show forest plot			Other data	No numeric data

2 Life‐table rates per 100 women for discontinuation due to personal reasons (6‐month) Show forest plot			Other data	No numeric data

3 Life‐table rates per 100 women for discontinuation due to personal reasons (12‐month) Show forest plot			Other data	No numeric data

Comparison 1. Collatex vaginal sponge (nonoxynol‐9 1.15 g) versus Neo Sampoon tablet (menfegol 60 mg)

Ir a la tabla de la revisión

Comparison 2. Ortho vaginal tablets: nonoxynol‐9 100 mg versus menfegol 60 mg

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Life‐table rates per 100 women for pregnancy (6‐month) Show forest plot			Other data	No numeric data

2 Life‐table rates per 100 women for pregnancy (12‐month) Show forest plot			Other data	No numeric data

3 Pearl index per 100 woman‐years Show forest plot			Other data	No numeric data

4 Life‐table rates per 100 women for discontinuation due to discomfort Show forest plot			Other data	No numeric data

Comparison 2. Ortho vaginal tablets: nonoxynol‐9 100 mg versus menfegol 60 mg

Ir a la tabla de la revisión

Comparison 3. Ortho or Emko tablet (nonoxynol‐9 100 mg) versus Neo Sampoon tablet (menfegol 60 mg)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Life‐table rates per 100 women for pregnancy Show forest plot			Other data	No numeric data

2 Life‐table rates per 100 women for discontinuation due to discomfort and/or medical reasons Show forest plot			Other data	No numeric data

Comparison 3. Ortho or Emko tablet (nonoxynol‐9 100 mg) versus Neo Sampoon tablet (menfegol 60 mg)

Ir a la tabla de la revisión

Comparison 4. Ortho tablet (nonoxynol‐9 100 mg) versus Emko tablet (nonoxynol‐9 100 mg)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Life‐table rates per 100 women for pregnancy Show forest plot			Other data	No numeric data

2 Life‐table rates per 100 women for discontinuation due to discomfort Show forest plot			Other data	No numeric data

Comparison 4. Ortho tablet (nonoxynol‐9 100 mg) versus Emko tablet (nonoxynol‐9 100 mg)

Ir a la tabla de la revisión

Comparison 5. Emko foam (nonoxynol‐9 8% concentration) versus Neo Sampoon tablet (menfegol 60 mg)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Life‐table rates per 100 women for pregnancy (12‐month) Show forest plot			Other data	No numeric data

2 Life‐table rates per 100 women for discontinuation due to discomfort (12‐month) Show forest plot			Other data	No numeric data

Comparison 5. Emko foam (nonoxynol‐9 8% concentration) versus Neo Sampoon tablet (menfegol 60 mg)

Ir a la tabla de la revisión

Comparison 6. Ortho tablet (nonoxynol‐9 100 mg) versus VCF film (nonoxynol‐9 72 mg)

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Probability of pregnancy through six months of typical use Show forest plot			Other data	No numeric data

Comparison 6. Ortho tablet (nonoxynol‐9 100 mg) versus VCF film (nonoxynol‐9 72 mg)

Ir a la tabla de la revisión

Comparison 7. Nonoxynol‐9 gels (52.5 mg, 100 mg, 150 mg); Nonoxynol‐9 film 100 mg; Nonoxynol‐9 suppository 100 mg

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Probability of pregnancy through six months of typical use Show forest plot			Other data	No numeric data

2 Discontinued method early Show forest plot			Other data	No numeric data

3 Liked the method "very much" Show forest plot			Other data	No numeric data

Comparison 7. Nonoxynol‐9 gels (52.5 mg, 100 mg, 150 mg); Nonoxynol‐9 film 100 mg; Nonoxynol‐9 suppository 100 mg

Ir a la tabla de la revisión

The Cochrane Library

Scolaris Language Selector Scolaris Language Selector

Idioma de la Revisión Cochrane

Idioma de la web

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet

Scolaris Content Display Scolaris Content Display

Temas

Scolaris Language Selector Scolaris Language Selector

Scolaris Content Display Scolaris Content Display

Instituciones a las que se accedió previamente

Scolaris Content Display Scolaris Content Display

Usuarios institucionales

Instituciones a las que se accedió previamente

Otras opciones de acceso

	Idioma de la Revisión Cochrane Escoja su idioma de preferencia para las revisiones Cochrane y otros contenidos. Las secciones sin una traducción aparecerán en inglés.

	Idioma de la web Escoja su idioma de preferencia para la web de la Biblioteca Cochrane.

Idioma de la Revisión Cochrane

Idioma de la web

Contenido relacionado

Revisiones y protocolos relacionados

Temas

Copiar o descargar referencia

Idioma de la Revisión Cochrane

Idioma de la web

Instituciones a las que se accedió previamente

Usuarios institucionales

Instituciones a las que se accedió previamente

Otras opciones de acceso